Idelalisib Completed Phase 1 Trials for Recurrent Follicular Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01644799Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma